Related references
Note: Only part of the references are listed.Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein
Wei Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy
Fares Bassil et al.
MOVEMENT DISORDERS (2015)
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
Johannes Levin et al.
ACTA NEUROPATHOLOGICA (2014)
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
Ariadna Recasens et al.
ANNALS OF NEUROLOGY (2014)
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice
Meike Diepenbroek et al.
HUMAN MOLECULAR GENETICS (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
Mari H. Savolainen et al.
NEUROBIOLOGY OF DISEASE (2014)
Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies
Pierre-Olivier Fernagut et al.
NEUROBIOLOGY OF DISEASE (2014)
Age-Related Motor Dysfunction and Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy
P. O. Fernagut et al.
SYNAPSE (2014)
Alpha-synuclein spreading in Parkinson's disease
Ariadna Recasens et al.
FRONTIERS IN NEUROANATOMY (2014)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy
F. M. Noe et al.
NEUROBIOLOGY OF DISEASE (2013)
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
T. T. Myohanen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Nunilo Cremades et al.
CELL (2012)
Proteolytic Cleavage of Extracellular α-Synuclein by Plasmin IMPLICATIONS FOR PARKINSON DISEASE
Kwang Soo Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer
Bruno Fauvet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
ANIMAL MODELS OF MULTIPLE SYSTEM ATROPHY
P. -O. Fernagut et al.
NEUROSCIENCE (2012)
α-SYNUCLEIN PHOSPHORYLATION AND TRUNCATION ARE NORMAL EVENTS IN THE ADULT HUMAN BRAIN
G. Muntane et al.
NEUROSCIENCE (2012)
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
Benjamin Dehay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death
Dong-Hee Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Interleukin-1β Biosynthesis Inhibition Reduces Acute Seizures and Drug Resistant Chronic Epileptic Activity in Mice
Mattia Maroso et al.
NEUROTHERAPEUTICS (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
alpha-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease
Pavan K. Auluck et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 26 (2010)
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation
Junchao Tong et al.
BRAIN (2010)
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology
Ayse Ulusoy et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2010)
EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity
Jan Bieschke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons
Joao Paulo L. Daher et al.
MOLECULAR NEURODEGENERATION (2009)
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis
Luigi Franchi et al.
NATURE IMMUNOLOGY (2009)
In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1β in the murine brain
Rozenn Mingam et al.
BRAIN BEHAVIOR AND IMMUNITY (2008)
Second consensus statement on the diagnosis of multiple system atrophy
S. Gilman et al.
NEUROLOGY (2008)
Behavioral and histopathological consequences of paraquat intoxication in mice:: Effects of α-synuclein over-expression
P. O. Fernagut et al.
SYNAPSE (2007)
Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy:: Implications for multiple system atrophy
Nadia Stefanova et al.
MOVEMENT DISORDERS (2007)
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18
Woods Wannamaker et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Calpain-cleavage of α-synuclein -: Connecting proteolytic processing to disease-linked aggregation
Brian M. Dufty et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein
Igor F. Tsigelny et al.
FEBS JOURNAL (2007)
Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo
Magali Periquet et al.
JOURNAL OF NEUROSCIENCE (2007)
The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's Disease
A. W. Michell et al.
CELL TRANSPLANTATION (2007)
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein (1-120):: Implications for Lewy body disorders
GK Tofaris et al.
JOURNAL OF NEUROSCIENCE (2006)
Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases
JY Sung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A precipitating role for truncated α-synuclein and the proteasome in α-synuclein aggregation -: Implications for pathogenesis of Parkinson disease
CW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the neuropathology of multiple system atrophy
N Stefanova et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations
WX Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Animal models of multiple system atrophy
N Stefanova et al.
TRENDS IN NEUROSCIENCES (2005)
Impact of the acidic C-terminal region comprising amino acids 109-140 on α-synuclein aggregation in vitro
W Hoyer et al.
BIOCHEMISTRY (2004)
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein
SM Fleming et al.
JOURNAL OF NEUROSCIENCE (2004)
Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro
AJ Mishizen-Eberz et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Role of α-synuclein carboxy-terminus on fibril formation in vitro
IVJ Murray et al.
BIOCHEMISTRY (2003)
Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes
PJ Kahle et al.
EMBO REPORTS (2002)
The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease
BCV Campbell et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein
JC Rochet et al.
BIOCHEMISTRY (2000)
Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
LC Serpell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy
KA Conway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
